McKinsey January 9, 2025
Leading companies are revamping research and early development to curb lengthy drug development timelines and rising costs.
The journey to bring new medicines to market remains long and costly, despite recent technological and process improvements in biopharma R&D. It takes about a decade, on average, from candidate nomination to launch, and study and application costs for investigational new drugs (INDs) have soared in recent years by 20–30 percent.
These challenges stem partly from the growing complexity of research and early development, fueled by an explosion of data and insights generated by experiments conducted across diverse therapeutic areas. To assess a drug candidate’s clinical potential, researchers need to efficiently analyze vast amounts of information, considering factors like structure, target binding, modulation...
Today's Sponsors
Today's Sponsor
